福元医药：FY101注射液正在按计划进行I期临床实验，目前获得的I期临床效果达到预期

Core Viewpoint - Fuyuan Pharmaceutical (601089) is progressing with its FY101 injection in Phase I clinical trials, achieving expected results [1] Group 1 - The company is conducting Phase I clinical trials for its FY101 injection as planned, with results meeting expectations [1] - The company plans to submit an IND application for its self-developed new drug FY103 injection by December 2025, which has already received acceptance for clinical trial application at the end of 2025 [1] - The company commits to timely disclosure of project progress in accordance with information disclosure requirements upon obtaining clinical trial approval and officially starting clinical research [1]